Akèy › Dyabèt tip 1
Etid klinik pou Dyabèt tip 1 ap rekrite nan Etazini
137 etid pou Dyabèt tip 1 ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Aurora, CO23 etid
- Boston, MA21 etid
- Seattle, WA18 etid
- Chicago, IL16 etid
- New Haven, CT15 etid
- New York City, NY15 etid
- San Francisco, CA14 etid
- Indianapolis, IN13 etid
- Miami, FL13 etid
- Gainesville, FL12 etid
- Philadelphia, PA11 etid
- Atlanta, GA11 etid
- Minneapolis, MN10 etid
- Durham, NC10 etid
- Charlottesville, VA9 etid
- Houston, TX9 etid
- Nashville, TN8 etid
- Cleveland, OH7 etid
- Dallas, TX7 etid
- Orlando, FL7 etid
- Pittsburgh, PA7 etid
- Los Angeles, CA6 etid
- Buffalo, NY6 etid
- Kansas City, MO6 etid
- Baltimore, MD6 etid
- San Diego, CA6 etid
- Columbus, OH6 etid
- Detroit, MI5 etid
- Jacksonville, FL5 etid
- Tampa, FL5 etid
- Memphis, TN4 etid
- Louisville, KY4 etid
- Rochester, MN4 etid
- Baldwin Park, CA4 etid
- Mountain View, CA4 etid
- Ann Arbor, MI3 etid
- Austin, TX3 etid
- St. Louis, MO3 etid
- Concord, CA3 etid
- Portland, OR3 etid
Pa eta
- Arizona3 etid
- Colorado24 etid
- Connecticut16 etid
- Florid30 etid
- Georgia13 etid
- Illinois16 etid
- Indiana13 etid
- Kalifòni37 etid
- Kentucky6 etid
- Maryland6 etid
- Massachusetts21 etid
- Michigan8 etid
- Minnesota13 etid
- Missouri9 etid
- New York23 etid
- North Carolina12 etid
- Ohio13 etid
- Oregon3 etid
- Pennsylvania13 etid
- Tennessee11 etid
- Texas16 etid
- Utah5 etid
- Virginia10 etid
- Washington20 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Starting Technology in At Risk Type 1 Diabetes Study
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06453928App-Based Certified Diabetes Education Therapy (AB-CDE)
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07282639A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 23, 2026 · NCT07803744ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
Ap rekrite
Laj 8 a 21 · Tout sèks · Mizajou Sep 23, 2026 · NCT05463289A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Ap rekriteFaz 3
Laj 1 a 35 · Tout sèks · Mizajou Sep 22, 2026 · NCT07222332A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Ap rekriteFaz 3
Laj 1 a 35 · Tout sèks · Mizajou Sep 22, 2026 · NCT07222137Type 1 Diabetes Extension Study
Ap rekriteEtid obsèvasyon
Laj 8 a 35 · Tout sèks · Mizajou Sep 18, 2026 · NCT02734277METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
Ap rekriteFaz 2
Laj 18 a 69 · Tout sèks · Mizajou Sep 15, 2026 · NCT07699380A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Ap rekriteFaz 3
Laj 1 a 25 · Tout sèks · Mizajou Sep 14, 2026 · NCT07088068CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Ap rekriteFaz 1/2
Laj 12 a 35 · Tout sèks · Mizajou Sep 11, 2026 · NCT06783309Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
Ap rekriteFaz 2
Laj 4 a 34 · Tout sèks · Mizajou Sep 9, 2026 · NCT07216391C-Carbs: A CGM-guided Approach to Teaching Carb Awareness
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07807280Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes
Ap rekrite
Laj 16 a 50 · Tout sèks · Mizajou Sep 8, 2026 · NCT05540704Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Ap rekriteFaz 2
Laj 8 a 45 · Tout sèks · Mizajou Sep 8, 2026 · NCT07142252The iLet Experience Study
Ap rekriteEtid obsèvasyon
Laj 6 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06891898A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Ap rekriteFaz 1/2
Laj 9 a 20 · Tout sèks · Mizajou Sep 2, 2026 · NCT07061574Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
Ap rekrite
Laj 8 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT05268250A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT04786262Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599982HLA Demographics Study in Adults With Type 1 Diabetes
Ap rekriteEtid obsèvasyon
Laj 18 a 55 · Tout sèks · Mizajou Aug 28, 2026 · NCT06860516Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
Ap rekriteVolontè an sante akeyi
Laj 18 a 90 · Tout sèks · Mizajou Aug 28, 2026 · NCT07254364Family Intervention for Black Teens With Type 1 Diabetes
Ap rekrite
Laj 10 a 14 · Tout sèks · Mizajou Aug 27, 2026 · NCT06275412Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching
Ap rekriteVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Aug 27, 2026 · NCT07766811Long-Term Outcomes of Teplizumab in Routine Clinical Care
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 25, 2026 · NCT07360080SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Ap rekriteFaz 2
Laj 5 a 40 · Tout sèks · Mizajou Aug 24, 2026 · NCT07187531Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.